Association of Atrial Septal Aneurysm and Shunt Size With Stroke Recurrence and Benefit From Patent Foramen Ovale Closure.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 11 2022
Historique:
pubmed: 11 10 2022
medline: 18 11 2022
entrez: 10 10 2022
Statut: ppublish

Résumé

The Patent Foramen Ovale (PFO)-Associated Stroke Causal Likelihood classification system combines information regarding noncardiac patient features (vascular risk factors, infarct topography) and PFO features (shunt size and presence of atrial septal aneurysm [ASA]) to classify patients into 3 validated categories of responsiveness to treatment with PFO closure. However, the distinctive associations of shunt size and ASA, alone and in combination, have not been completely delineated. To evaluate the association of PFO closure with stroke recurrence according to shunt size and/or the presence of an ASA. Pooled individual patient data from 6 randomized clinical trials conducted from February 2000 to October 2017 that compared PFO closure with medical therapy. Patients in North America, Europe, Australia, Brazil, and South Korea with PFO-associated stroke were included. Analysis was completed in January 2022. Transcatheter PFO closure plus antithrombotic therapy vs antithrombotic therapy alone, stratified into 4 groups based on the combination of 2 features: small vs large PFO shunt size and the presence or absence of an ASA. Recurrent ischemic stroke. A total of 121 recurrent ischemic strokes occurred in the pooled 3740 patients (mean [SD] age, 45 [10] years; 1682 [45%] female) during a median (IQR) follow-up of 57 (23.7-63.8) months. Treatment with PFO closure was associated with reduced risk for recurrent ischemic stroke (adjusted hazard ratio [aHR], 0.41 [95% CI, 0.28-0.60]; P < .001). The reduction in hazard for recurrent stroke was greater for patients with both a large shunt and an ASA (aHR, 0.15 [95% CI, 0.06-0.35]) than for large shunt without ASA (aHR, 0.27 [95% CI, 0.14-0.56]), small shunt with ASA (aHR, 0.36 [95% CI, 0.17-0.78]), and small shunt without ASA (aHR, 0.68 [95% CI, 0.41-1.13]) (interaction P = .02). At 2 years, the absolute risk reduction of recurrent stroke was greater (5.5% [95% CI, 2.7-8.3]) in patients with large shunt and ASA than for patients in the other 3 categories (1.0% for all). Patients with both a large shunt and an ASA showed a substantially greater beneficial association with PFO closure than patients with large shunt alone, patients with small shunt and ASA, and patients with neither large shunt nor ASA. These findings, combined with other patient features, may inform shared patient-clinician decision-making.

Identifiants

pubmed: 36215079
pii: 2796820
doi: 10.1001/jamaneurol.2022.3248
pmc: PMC9552048
doi:

Substances chimiques

Fibrinolytic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1175-1179

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002544
Pays : United States

Commentaires et corrections

Type : CommentIn

Auteurs

Jean-Louis Mas (JL)

GHU Paris Psychiatrie et Neurosciences, Hôpital Sainte-Anne, Service de Neurologie, Institut de Psychiatrie et Neurosciences de Paris, Université de Paris-Cité, Paris, France.

Jeffrey L Saver (JL)

Comprehensive Stroke Center and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles.

Scott E Kasner (SE)

Comprehensive Stroke Center, Department of Neurology, University of Pennsylvania Medical Center, Philadelphia.

Jason Nelson (J)

Predictive Analytics and Comparative Effectiveness Center, Tufts Medical Center/Tufts University School of Medicine, Boston, Massachusetts.

John D Carroll (JD)

Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora.

Gilles Chatellier (G)

Centre d'Investigations Cliniques, Unité de Recherche Clinique, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.

Geneviève Derumeaux (G)

Département de Physiologie, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, INSERM U955, Université Paris-Est Créteil (UPEC), Créteil, France.

Anthony J Furlan (AJ)

Department of Neurology, Case Western Reserve University, Cleveland, Ohio.

Howard C Herrmann (HC)

Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

Peter Jüni (P)

Applied Health Research Centre, Li Ka Shing Knowledge Institute of St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Jong S Kim (JS)

Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Benjamin Koethe (B)

Predictive Analytics and Comparative Effectiveness Center, Tufts Medical Center/Tufts University School of Medicine, Boston, Massachusetts.

Pil Hyung Lee (PH)

Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Benedicte Lefebvre (B)

Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.

Heinrich P Mattle (HP)

Department of Neurology, Bern University Hospital, Bern, Switzerland.

Bernhard Meier (B)

University of Bern, Bern, Switzerland.

Mark Reisman (M)

Weill Cornell Medical Center, New York, New York.

Richard W Smalling (RW)

Division of Cardiology, Department of Medicine, UTHealth/McGovern Medical School and The Memorial Hermann Heart and Vascular Institute, Houston, Texas.

Lars Sondergaard (L)

Department of Cardiology, University of Copenhagen Hospital Rigshospitalet, Denmark, Copenhagen.

Jae-Kwan Song (JK)

Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

David E Thaler (DE)

Department of Neurology, Tufts Medical Center/Tufts University School of Medicine, Boston, Massachusetts.

David M Kent (DM)

Predictive Analytics and Comparative Effectiveness Center, Tufts Medical Center/Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH